Amgen’s MariTide shows up to 20% average weight loss in Phase 2 study
Amgen (AMGN) announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide – maridebart cafraglutide, formerly AMG 133 -, an investigational antibody peptide conjugate subcutaneously administered monthly or less frequently.
Amgen's monthly obesity drug matches competition in phase 2, but investors are unimpressed
MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight loss of up to 20% over 52 weeks in individuals living with obesity or overweight but without type 2 diabetes. For those with diabetes, the average weight loss reached 17%.
Goldman Sachs analyst Salveen Richter has maintained their bullish stance on AMGN stock, giving a Buy rating yesterday.Don't Miss our Black ...
Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 5 a.m. PT on Tuesday, Nov. 26, 2024, to ...
Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.
We think Amgen’s phase 2 data for obesity drug candidate maritide shows evidence of a differentiated convenience profile (monthly or less frequent injections versus weekly injections for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback